Critical Outcome Technologies Inc. is a bioinformatics company that uses its proprietary CHEMSAS platform to reduce the time and cost of drug discovery. Its lead compound, COTI-2, shows promise for treating cancers with p53 mutations and is nearly ready for Phase 1 clinical trials. If successful, COTI-2 could generate hundreds of millions in licensing deals. The company also has additional compounds in development and collaborations that could produce milestone payments in the coming years. Critical Outcome Technologies aims to revolutionize drug discovery through computational simulation and reduce the traditional multi-billion dollar and decade-long process.

1. The future of drug discovery has arrived
Reducing development time, cost & risk
Investor Presentation | March 2014

2. Disclaimer
When used anywhere in this presentation, whether oral or written, the words expects,
believes, anticipates, estimates and similar expressions are intended to identify forwardlooking statements. Forward-looking statements may include statements addressing future
financial and operating results of Critical Outcome Technologies Inc. (COTI).
COTI bases these forward-looking statements on its current expectations about future
events. Such statements are subject to risks and uncertainties including, but not limited to,
the successful implementation of COTI’s strategic plans, the acceptance of new products,
the obsolescence of existing products, the resolution of potential patent issues,
competition, changes in economic conditions, and other risks described in COTI’s public
documents such as press releases and filings with the Toronto Stock Exchange and the
Ontario Securities Commission.
All forward-looking statements are qualified in their entirety by the cautionary statements
included in this document and such filings. These risks and uncertainties could cause actual
results to differ materially from results expressed or implied by forward-looking statements
contained in this presentation. These forward-looking statements speak only as of the date
of this presentation.
TSXV: COT
2

3. Critical Outcome Technologies Inc.
 A bioinformatics
and accelerated
drug discovery
company
 Listed on the TSX-V
under the symbol COT
since 2006
TSXV: COT
3

4. Investment highlights
1
2
Potential cancer breakthrough drug
candidate is nearly Phase 1 ready
3
TSXV: COT
We reduce the time, cost & risk of
bringing new drugs to market
We have many more revenue
opportunities in our pipeline
4

5. Conventional drug development
is a long & expensive process
characterized by a high risk
of failure
TSXV: COT
11 – 15
years
$1 billion
or more
1 FDA
approval
5

6. What we do
 Reduce drug discovery, optimization & lead
selection by 1.5 to 3 yrs.
 Saving significant $$$
 Increasing revenue period under patent
protection
TSXV: COT
6

7. How we do it – CHEMSAS®
Proprietary,
artificial intelligence
based drug
discovery platform
technology
TSXV: COT
7

8. Advantages of CHEMSAS®
Computational
replication of
traditional
‘wet lab’ drug
discovery process
TSXV: COT
Failed attempts occur
quickly & cheaply in
computer simulations,
not the ‘wet lab’
Higher probability of
clinical & commercial
success
8

9. Potential cancer breakthrough
Our lead compound,
COTI-2, is effective
against cancers with
mutations of the p53
gene
TSXV: COT
9

10. Why COTI-2 is exciting
 > 50% of all human cancers have a p53 mutation
(eg. ~ 95% of ovarian cancers)
 Mechanism of action confirmed by thought leader
Dr. Gordon Mills at MD Anderson Cancer Center
(June 2013)
 Novel, first-in-class
 Strong IP protection in place
TSXV: COT
10

11. COTI-2 is (nearly) Phase 1 ready
 In final 2-species toxicity studies – completion in first
half of 2014
 FDA IND filing expected in second half of 2014 (leading
to Phase 1 clinical trial)
 Pursuing orphan drug and/or breakthrough therapy
status
 Signed an LOI with a strategic partner, Portage Biotech
Inc., for clinical development
TSXV: COT
11

12. COTI-2 = significant revenue potential
 Top 5 2012 Phase 1/2 oncology licensing deals
disclosed (1):
 Upfront payments of approx. $25-$92 million
 Milestone payments between $550-$1,100 million
 Royalties on net sales
 1st half of 2013 (2) – 16 Phase 1 licensing deals with 6
in cancer – avg. upfront $30m
TSXV: COT
(1)
(2)
Medius Associates
Thomson Reuters
12

13. Other revenue opportunities
 Robust internal pipeline of compounds
- AML, colorectal cancer, small cell lung cancer library, MS, etc.
 3 existing R&D collaborations expected to bring in
milestone payments beginning late 2014 / 2015
- Western University
- Delmar Chemicals
- Major Pharma Co.
TSXV: COT
13

14. Looking ahead
Other CHEMSAS® applications:
 CHEMFirm – Small molecule
profiling & investment due
diligence tool
 Drug library profiling –
Based on customer identified
criteria
 Drug repurposing – Finding
new purposes for drugs
coming off patent
TSXV: COT
14

15. Project ROSALIND
 Programmable computer
simulation of human cancer
cell signaling
 Better personalized
treatment decisions based
on genetic profile of one’s
cancer
 Personalized cancer gene
profiling projected to be
*
~ $35B market by 2018
TSXV: COT
*
Markets and Markets (2013)
15

16. Summary
1
2
Potential cancer breakthrough drug
candidate is nearly Phase 1 ready
3
TSXV: COT
We reduce the time, cost & risk of
bringing new drugs to market
We have many more revenue
opportunities in our pipeline
16

17. The future of drug discovery has arrived
Reducing development time, cost & risk
Dr. Wayne Danter
President & CEO
Tel: (519) 858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com
www.facebook.com/criticaloutcome
twitter.com/criticaloutcome
www.slideshare.net/criticaloutcome